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ABSTRACT
Objective Among people with Marfan syndrome who
have a typical aortic root aneurysm, dissection is a
characteristic cause of premature death. To pre-empt Type
A dissection, composite root replacement with a
mechanical valve became the standard of care in the
1980s and 1990s. This is being superseded by valve-
sparing aortic root replacement to avoid lifelong
anticoagulation. In 2004, a total root and valve-sparing
procedure, personalised external aortic support, was
introduced. We report here results among the ﬁrst 30
recipients.
Methods From cross-sectional digital images, the
patient’s own aorta is modelled by computer aided design
and a replica is made in thermoplastic by rapid
prototyping. On this, a personalised support of a
macroporous polymer mesh is manufactured. The mesh is
positioned around the aorta, closely applied from the
aortoventricular junction to beyond the brachiocephalic
artery. The operation is performed with a beating heart and
usually without cardiopulmonary bypass.
Results Between 2004 and 2011, 30 patients, median
age 28 years (IQR 20–44) had this operation and have
been prospectively followed for 1.4–8.8 years by February
2013. During a total of 133 patient-years there were no
deaths or cerebrovascular, aortic or valve-related events.
These early outcomes are better than published results for
the more radical extirpative root replacement operations.
Conclusions The aortic valve, the root architecture, and
the blood/endothelia interface are conserved. The
perioperative burden is less and there has been freedom
from aortic and valvular events. A prospective comparative
study is planned.
INTRODUCTION
Standard surgical management of aortic root aneur-
ysm in Marfan patients is either total root replace-
ment (TRR) or valve-sparing root replacement
(VSRR). Current ESC/EACTS guidelines for the
management of valvular heart disease state that,
whatever the severity of aortic regurgitation (AR),
surgery should be considered in patients with
Marfan syndrome, with risk factors (family history
of dissection, size increase 2 mm/year in repeated
examinations) who have aortic root disease with
maximal ascending aortic diameter of ≥45 mm
(Class IIa, Level C evidence).1
The placement of a personalised external aortic
root support (PEARS), computer designed and
manufactured to match the aortic root morphology
of the individual patient, was introduced in 2004
as a conservative approach for Marfan patients.
The device manufacture and operative method
were the result of research and development
between 2000 and 2004 when the ﬁrst operation
was performed.2 The computer aided design
(CAD), manufacturing method and surgical tech-
nique have all remained consistent without the
iterative development which has characterised the
evolution of both TRR and VSRR.3 After proof of
principle4 and prospective evaluation in the ﬁrst 20
patients,5 6 the technique has undergone Health
Technology Appraisal by the British National
Institute for Health and Care Excellence (NICE).7
The purpose of this analysis is to describe the
consecutive cohort of the ﬁrst 30 patients to have
undergone this procedure in two centres, the Royal
Brompton Hospital, London, UK and the
University of Leuven, Belgium, and who have had
at least 1 year of follow-up. In this report, patient
characteristics, procedural details and clinical out-
comes to date will be presented. Survival and the
incidence of aortic valve-related events are com-
pared with a published meta-analysis of 1385
patients who received the current standard surgical
treatments (TRR and VSRR)8 9 to discover whether
outcomes following PEARS approach equivalence
with those following the existing standard of care.
METHODS
PEARS technology employs spatial data from MRI
or CT images to create a CAD model from which a
replica of the individual aorta is made by rapid
prototyping (RP) (ﬁgure 1). On this former, a mesh
support, customised for the individual patient, is
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manufactured from a macroporous textile knitted from a
medical grade polymer yarn.4 The surgical method has been
fully described.10 Brieﬂy, the chest is opened through median
sternotomy and the aorta is dissected proximally to the aorto
ventricular junction, including creating space proximal to the
coronary arteries for passage of the support. The mesh is
removed from the former by opening the seam. The positions
of the coronary ostia are indicated on the former and the mesh
is incised to accommodate them (ﬁgure 2). The support is posi-
tioned around the aorta and the coronary arteries. The closing
seam is secured.
Patients diagnosed with Marfan syndrome and other aortopa-
thies have routine interval aortic root measurements with echo and
the general criteria for intervention are agreed.1 Criteria for ﬁrst
use of the procedure agreed with the Royal Brompton Hospital
Research ethics committee were that patients should have little or
no AR, and an ascending aortic root diameter of 40–45 mm.
Statistical methods
Standard descriptive statistical analyses were done with IBM SPSS
V.20. Continuous variables are summarised as mean±SD, median
±IQR, and range. Categorical data are presented as counts and
proportions. Overall non-parametric survival estimates were
obtained by the method of Kaplan and Meier. Linearised occur-
rence rates are calculated by dividing the number of events by
accumulated patient years and expressed as % per patient year.
Comparison with existing standards
Meta-analytic analyses were done employing MS Excel 2007.
Since patients in the PEARS dataset were operated upon elec-
tively to prevent further root dilatation, and may differ with
regard to preoperative characteristics from patients undergoing
TRR or VSRR, we performed additional weighted pooling of
the baseline characteristics: patient age, preoperative root diam-
eter, proportion of patients presenting with dissection, and the
operative mortality in the Benedetto study.8 The weighted
pooling was done employing inverse variance weighting, and in
case of pooling of proportions, the natural log transformation
was employed. In case of absent early mortality in a particular
study, for the purpose of pooling the data, we assumed that
operative mortality was 0.5%.
RESULTS
Of 33 patients clinically evaluated, these 30 patients were
offered PEARS surgery. We have not turned anyone down yet
on grounds of anatomy, but there are two patients with mea-
surements at 42 mm who have shown no enlargement over
18 months, but are having 6-monthly MRI measurement. One
more has been affected by paroxysmal atrial ﬁbrillation and
whose aortic root has been 43 mm for last 3 years. These three
patients are below root replacement criteria and remain candi-
dates for PEARS.
Figure 1 Technical aspects of the support. The panels from left to right show the measurements made on the MRI and the model created from it
by computer aided design. The next panel shows the former, a replica of the aorta in thermoplastic, made by rapid prototyping (commonly called
3-D printing29) and the soft macroporous mesh sleeve supported by it. The schematic shows the relationship of the support to the aortoventricular
junction (below) and to the coronary and brachiocephalic arteries. Finally, the before and eight years after MRI scans showing complete
conservation of the aortic root architecture and, therefore, the aortic valve support.
Figure 2 Surgical details of the opening made in the mesh for a coronary artery, the surgical dissection below the left coronary artery, and the
mesh being passed below (proximal) to it.10
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Baseline
Table 1 displays patient and procedural characteristics. Of the
30 operations, 26 were performed at Royal Brompton Hospital
(RBH) and four at Universitair Ziekenhuis Leuven, 23 by JP,
four by FR and three by MP. The accrual rate was approximately
linear and largely reﬂects the rate of Marfan patients presenting
for surgery at RBH.
One patient had corrective surgery of a pectus excavatum at
the time of the aortic root surgery.
Perioperative serious adverse events
One patient had recurrent ischaemia on several attempts to
close the suture line in the external support. It was known that
there was a small non-dominant right coronary artery which
raised the suspicion of short left main coronary anatomy. The
chest was closed and the patient recovered. Coronary angiog-
raphy conﬁrmed that suspicion, and with the imaging available,
the support was safely positioned a few days later.
One patient had a ventricular ﬁbrillation arrest in the intensive
care unit. The emergency team released the closing suture and
the heart rhythm became stable with restoration of a normal
ECG. Subsequent imaging has shown the aortic dimensions to be
stable. The situation remains under interval monitoring.
Follow-up
Average patient follow-up was 4.4 years, ranging from 1.4 to
8.8 years, with a total follow-up of 133 patient years. Follow-up
was complete in 100% of patients until February 2013. During
follow-up, no deaths occurred, and cumulative survival was
100% at 7 years. It should be recognized that at 7 years post-
operative only ﬁve of the original 30 patients were still at risk.
There were no medical or surgical events related to the aorta
or aortic valve. There have been no neurologic events.
Serious adverse events
During follow-up there was one patient who experienced
exercise-induced constricting chest pain 6.7 years after the pro-
cedure (linearised occurrence rate 0.75%/patient year). Exercise
ECG showed ischaemic ST depression. It was found to be unre-
lated to the aortic root pathology or surgery. Coronary angiog-
raphy revealed the cause of angina to be an atherosclerotic left
anterior descending coronary artery stenosis which was success-
fully stented. Aortography and coronary angiography performed
at that time showed widely patent coronary oriﬁces with no sign
of impingement of the external support on the smooth lumen
of his coronary arteries.11
Cross-sectional survey
Of the 30 patients, 29 were in New York Heart Association
(NYHA) class I, and were either working or pursuing full-time
study. The one other patient was in NYHA class III and unﬁt for
work due to comorbidity predating surgery and unrelated to his
aortic root disease. He has chronic obstructive pulmonary disease,
pulmonary hypertension and multiple liver cysts which further
impede breathing. At the time of the patient survey, 26 of the 30
patients were on some kind of medication, predominately as con-
tinued protective treatment for their Marfan aortic disease: 19
patients received β blocker medication, three patients received
ACE inhibitor or AT II antagonist medication, two patients com-
bined β blocker medication with an ACE inhibitor or angiotensin
(AT) II antagonist. One patient was on antidepressant medication.
The patient in NYHA class III was the only patient requiring antic-
oagulation therapy (warfarin); additionally, he was on diuretics
and β blocker therapy.
Comparison with gold standard surgical results
Table 2 displays preoperative patient characteristics and post-
operative and late outcome in the PEARS population (n=30)
Table 1 Patient and procedural characteristics
Age
Mean (SD) 32 years (13)
Median (IQR) 28 years (20–44)
Range 15–57 years
Male:female ratio 20:10
Sinus rhythm 30 (100%)
Preoperative AR
None 21
Mild 8
Missing 1
Preop aortic root measurement method
MRI 23
CT 6
Echo 1
Preoperative aortic dimensions
Mean (SD) 46.2 mm (3.4)
Median (IQR) 47 mm (43–48)
Range 40–54 mm
Procedural duration
Mean (SD) 160 min (54)
Median (IQR) 145 min (136–165)
Range 85–414 min
Cardiopulmonary bypass (n (%); minutes) 1 (3%); 20 min
Blood loss (n=27)
Mean (SD) 287 mL (272)
Median (IQR) 150 mL (75–469)
Range 50–950 mL
Blood products (n (%))
Blood 1 (3%)
Platelets –
FFP 1 (3%)
Other 2 (6%)
ICU stay (hours)
Mean (SD) 25 h (12)
Median (IQR) 24 h (21.5–25.5)
Range 0–71 h
Postoperative hospital stay
Mean (SD) 6.6 days (SD 2.8)
Median (IQR) 6.0 days (4.8–7.0)
Range 4–16 days
Total hospital stay
Mean (SD) 9.0 days (5.4)
Median (IQR) 8.0 (6.0–9.3)
Range 5–33 days
Postoperative complications in hospital (n=29)
Death –
MI –
CVA –
Major bleeding –
Reoperation 1 (3%)
Other major adverse events* 3 (16%)
Alive at 30 days (100%)
30
*3 episodes of atrial fibrillation and 2 ventricular fibrillation arrests.
AR, aortic regurgitation; CVA, cerebrovascular accident; ICU, intensive care unit; MI,
myocardial infarction.
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and in the TRR (n=972) and VSRR (n=413) patient groups
from the Benedetto publication. Compared to the Benedetto
TRR and VSRR patient groups, patients in the PEARS dataset
were, on average, operated upon at a younger age with smaller
aortic root diameters. None had dissection at the time of
surgery or prior to it.
DISCUSSION
Clinical follow-up data on the ﬁrst 30 consecutive patients
undergoing PEARS who have had at least 1 year of follow-up
are presented. All patients in whom the intention was to
perform this surgery are included. There were no perioperative
deaths in this cohort of patients, 1–30.i There have been no
aortic, valve-related or cerebral events among these patients.
The 34th intended operation in December 2012, performed
after the closure of analysis, was abandoned and the patient sub-
sequently died. Details are provided below.
One limitation of the study is that magnitude and nature of
the denominator population from which these patients were
drawn cannot be reliably estimated, and the factors that inﬂu-
ence the decision from one clinical team to another have not
been documented.12 The Big Aortic Root Study (BARS) is being
designed to capture this process for all patients with root aneur-
ysm due to aortopathy.13
This is a small non-randomised study with a limited follow-up
duration, so any conclusions concerning longer-term results are
preliminary, and are made with caution, however, this is part of
a stepwise prospective evaluation of PEARS. We have already
established that the technical intentions of PEARS can be con-
sistently achieved: measurement of multiple before and after
images, made in random order without awareness of the iden-
tity of any image, showed that PEARS stabilises the size and
shape of the aortic root and sinuses4 (ﬁgure 3). Analysis of peri-
procedural variables, compared with similar patients having root
replacement surgery, conﬁrmed that the anticipated advantages
were achieved, cardiopulmonary bypass is not necessary, cardiac
and circulatory arrest are completely avoided, and that blood
product usage, operative time and hospital stay are commensur-
ately reduced.6
Meta-analysis of published results for root replacement
showed that the composite risk of a valve-related event
(thromboembolism, reintervention, endocarditis) among 972
patients who had TRR was 1.3% (95% CI 0.6 to 2.0), and for
413 who had VSRR it was 1.9 (95% CI 0.8 to 2.9).8 Of particu-
lar note is the reintervention rate of 1.3% for VSRR. More
recent published results from an expert group continue to show
this pattern of failure.14 None of these events have been seen
yet in PEARS. (table 2) Varying clinical characteristics among
the patient populations having TRR and VSRR, and a lack of
intention-to-treat analyses limit the value of these comparisons8 9
which will only be resolved by direct comparison including
random allocation of patients where equipoise for the surgical
options becomes evident.15
There are several factors that limit the validity of this com-
parison. Patients with severe AR are more likely to have TRR
and are not candidates for PEARS, so cannot be directly com-
pared. PEARS is used at smaller size, and therefore, earlier in
progression of the aortopathy, and this would create a lead time
bias in favour of PEARS during long-term follow-up.
Conversely, for patients who wait longer to meet the size criteria
for a TRR with a mechanical valve, there is an immortal time
bias: having surgery is conditional on having lived to reach the
greater aortic root size. We believe that only by prospective data
collection to protocol, as envisaged in the BARS study, will we
be able to make corrections for these factors.
The intention of all three operations is most commonly to
prevent aortic dissection. According to natural history data
reported in 1972 for 257 people with Marfan syndrome,
median survival was 40–41 years for men and 48–49 years for
women. Among 72 patients who were dead at the time of life-
table analysis, the average age at death was 32 years.16 As moni-
toring has become easier, operative risks have reduced, and
awareness of the risk of dissection is heightened, root replace-
ment has been advocated at smaller size. The criterion has come
down from 60, through 55 and 50 mm 17–20 to the present rec-
ommendation of 45 mm.1 Earlier intervention introduces a new
problem for patients and those advising them. It has always
been possible that some patients having elective root replace-
ment were never destined to have root dissection, and so, as the
size criterion was lowered, there is likely to be an increasing
number of patients who undergo surgery without gaining any
years of life because their survival is determined by other
factors. To illustrate the problem, we can consider carotid end-
arterectomy for which there are randomised controlled trials to
Table 2 Comparison of PEARS with total root replacement (TRR) and valve-sparing root replacement (VSRR)
PEARS TRR Benedetto VSRR Benedetto
Preoperative patient characteristics
Mean patient age (years (SD)) 31 (12) 35 (0.5) 33 (0.64)
Mean preop AR diameter (mm (SD)) 46.2 (3.4) 61 (0.7) 52 (0.3)
Proportion of patients with dissection – 0.30 (0.01) 0.18 (0.02)
Postoperative and late outcome (% or %/year; (95% CI))
Early mortality – 4.1% (1.9 to 7.7) 3.2% (0.5 to 17.9)
Reintervention on AV – 0.3%/year (0.1 to 0.5) 1.3%/year (0.3 to 2.2)
Thromboembolic event – 0.7%/year (0.5 to 0.9) 0.3%/year (0.1 to 0.6)
Endocarditis – 0.3%/year (0.2 to 0.5) 0.2%/year (0 to 0.3)
Composite valve-related event – 1.3%/year (0.6 to 2.0) 1.9%/year (0.8 to 2.9)
AR, aortic root, AV, aortic valve; PEARS, personalised external aortic root support.
iThere was one late death after completion of this analysis. A patient
operated on in December 2008 at the age of 26 with an aortic diameter
of 42 mm was found dead in bed in May 2013. The aorta and valve
were intact and the external support was closely applied and ﬁrmly
adherent to the aorta. There was no evidence of dissection. The
coronaries were free of disease and without evidence of thrombosis or
any other abnormality. The forensic pathologist found no cause of death
but presumed this was a sudden cardiac death in the context of Marfan
syndrome.
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evaluate the reduction in the risk of stroke. Using the ‘number
needed to treat’ calculation, the number of patients who have
an operation in order to prevent one stroke is six. These are
patients with neurological symptoms, and a carotid stenosis
greater than 70%, for whom the evidence for beneﬁt is most
compelling, yet ﬁve out of six patients having the operation gain
no beneﬁt from it. For clinical recommendations and compara-
tive health economic evaluation, the number needed to treat to
prevent a dissection in Marfan syndrome would be a useful stat-
istic, not at present available. An attempt at decision analysis
relied on best guesses from a handful of clinicians and, thus,
failed for want of data.12 21
The most frequently voiced concerns when PEARS has been
presented since its inception in 2004 are:
▸ The support will migrate and impinge on a coronary artery.
▸ A ‘wrapped’ aorta characteristically thins.
▸ Aortic dissection may occur within the support.
▸ The aorta will dilate beyond the support.
The ﬁrst concern arises because of the misconception that
PEARS is akin to wrapping of aneurysms, promulgated in the
1990s.22 Cut up portions of rigid low-porosity woven grafts
were placed around the aorta in an ad hoc fashion, an application
for which this material was never intended. There were instances
of its hard edges causing erosion of vessels.23 The material used
in PEARS is a soft, pliant, macroporous mesh which becomes
intimately incorporated in the outer layers of the aorta.24 25
There is no potential for ‘migration’. This has been conﬁrmed in
controlled laboratory experiments in sheep26 (Figure 4).
The second concern about aortic wall thinning is also an
extrapolation from misuse of vascular graft material.27 Careful
MRI monitoring reveals no sign of aortic wall thinning after
PEARS.4 Studies in sheep to address this question show that the
arterial wall thickens rather than thins26 (ﬁgure 4).
The strongest determinant of aortic dissection is the increasing
size of the aorta,18 19 and this is halted by PEARS.26 Intimate
apposition of the mesh can be achieved consistently (ﬁgure 5),
and the histological appearances suggest that dissection is
unlikely.26 Dissection in the supported aorta was not seen in a
20 year clinical experience (1984–2003) of external aortic
support with a macroporous mesh.25 We contend that if dissec-
tion were to occur, its consequences might be lessened and more
retrievable. However, no aortic root operation obviates all risks
and it is the overall outcome that is the measure of effectiveness.
Dilatation beyond the mesh (the fourth challenge) has not
been observed to date. Just as with TRR and VSRR, PEARS
itself cannot inﬂuence the course of Marfan syndrome or the
likelihood of dilation or dissection beyond the limits of
the support. The support in PEARS routinely extends beyond
the brachiocephalic artery, and is thus more protective than the
tube graft component of root replacement operations (ﬁgure 1).
Figure 3 All MRIs of the ﬁrst 10 patients before (left), and at intervals after, with the diameter of greatest change shown in red. Duplicate
measurements of 37 anonymised MRI images of Marfan aortic roots were presented with those of the patients in a random sequence.4 The black
circles show the read-reread variation in the controls, and the largest difference in the patients in red. The variability in read-reread is ampliﬁed by
choosing to display the one of three diameters with the largest difference, but illustrates the degree of imprecision that should be allowed for when
clinical decision are being made. The reduction in size of eight out of ten supported aortas because the aorta is held at the size it was on the
operating table illustrates the potential for restoration of aortic valve competence.
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The transition in TRR and VSRR is at a sutured anastomosis to
the remaining aorta, while with PEARS, there is a more gradual
transition in hoop strength from the ascending aorta to the
proximal arch. Any theoretical effect of dilation beyond the
operated segment is, therefore, less likely with PEARS.
There were no perioperative deaths in the ﬁrst 30 PEARS
patients, who are the subject of this planned analysis. There was
a subsequent postoperative death of the intended 34th patient
in December 2012, 5 days after surgery. We present the details
here for the purpose of full disclosure. The left main coronary
artery was tortuous with an upward loop, not demonstrated on
cross-sectional imaging. This was injured in the course of surgi-
cal dissection. Access was limited due to severe pectus excava-
tum, but exposure was considered adequate. The situation was
rapidly retrieved with a suture but transoesophageal echo
showed turbulent ﬂow and loss of myocardial contractility.
Cardiopulmonary bypass was rapidly instated and an internal
mammary artery graft placed. The aorta was opened and the
coronary oriﬁce inspected. Excellent ﬂow was conﬁrmed in the
native vessel and in the graft, but myocardial contractility did
not recover as would be expected, and myocardial stunning was
thought to be a factor. The external support was not positioned.
Biventricular support was instituted, and after 3–4 days, there
was good myocardial recovery, but 5 days after surgery, there
was acute onset ﬁxed dilatation of the pupils due to an intracer-
ebral bleed. It should be noted that although current mortality
with TRR and VSRR is considered to be low, in the
meta-analysis for TRR the mortality was 4.1% (CL 1.9–7.7) and
for VSRR 3.2% (CL 0.5–17.9). Furthermore, an unknown pro-
portion of intended VSRR operations were aborted and con-
verted to TRR or other operations, and thus, the results are
unreported in the follow-up studies.
PEARS has been the subject of prospective step-wise evalu-
ation, and has undergone formal technology appraisal by the
NICE for use in the British National Health Service.7 This is in
contrast with the iterative development of TRR and VSRR3 the
introduction of which antedated the now more formalised
approach to innovation and the introduction of new devices.
Evidence to date suggests that PEARS may offer equivalent pro-
tection to root replacement with lower early and late risk. A
direct comparative study is currently being planned.15 28 We
propose a prospective comparative study of the three operations
available for patients with aortic root aneurysms considered to
be at risk of dissection or regurgitation. At present, advice given
to patients tends to lead to the form of surgery preferred by the
team. The intention of the BARS is to ensure evidence-based
advice, uniform data acquisition and the possibility of random
allocation when equipoise exists.
Figure 5 A selection of the formers, which are replicas of the aortas of these patients indicating the variation in shape and size which can be
successfully modelled with this technique.
Figure 4 Biological incorporation of the mesh. The left-hand panels are of placement of a sleeve of the mesh around the carotid artery of a sheep,
and its appearance after ﬁve months. The macroscopic and histological appearances, with H&E and elastica stain are in the subsequent panels. The
mesh is incorporated, the vascular architecture is preserved and the endothelium never interfered with.26
974 Treasure T, et al. Heart 2014;100:969–975. doi:10.1136/heartjnl-2013-304913
Aortic and vascular disease
Key messages
What is already known about this subject
▸ The commonest cause of death among people with Marfan
syndrome is acute ascending aortic dissection most
frequently seen in young adult life.
▸ Current standard management is echocardiographic
monitoring with a view to replacement of the ascending
aorta, with or without aortic valve replacement.
▸ A novel operation using computer aided design to make a
personalised external aortic root support is now available,
and has had NICE Health Technology Appraisal.
▸ The surgery does not require opening the heart or aorta, or
any interference with the cerebral or myocardial perfusion,
and is usually performed without the need for
cardiopulmonary bypass.
What this study adds
▸ Clinical results up to 8.8 years for the ﬁrst 30 consecutive
patients are presented.
▸ There have been no aortic, cerebral or aortic valve-related
events at 133 patient-years of follow-up.
▸ This compares favourably with results for valve-sparing root
replacement which, on meta-analysis, was associated with
1.9%/year aortic valve-related events.
▸ Root replacement with a mechanical valve is followed by a
0.7%/year thromboembolic event rate, a risk avoided with
conservation of the patient’s aortic valve.
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